Literature DB >> 11258063

[Analysis of the prevention of post-ivermectin Loa loa encephalopathy by administration of initial low dose].

J Kamgno1, J Gardon, M Boussinesq.   

Abstract

A number of cases of Loa-encephalopathy have been reported following ivermectin (Mectizan) treatment for onchocerciasis in patients with high Loa microfilaraemia. A possible explanation for these severe reactions is the formation of micro-emboli in small brain vessels as a result of massive paralysis of Loa microfilariae in the blood. This suggests that encephalopathy might be prevented by giving an initial low dose of ivermectin to induce a more gradual action on the Loa microfilariae. To test this hypothesis, a trial was conducted on 23 adult patients in Cameroon. Patients were divided into two groups. One group received the recommended dose of 150 micrograms/Kg. The other group received a lower dose of 50 micrograms/Kg (one 3 mg tablet of Mectizan). Blood smears were made daily from day 1 to 7 after treatment and then on days 15 and 30. Results showed no difference in the effect of the dosage level on Loa microfilaraemia. This finding suggests that an initial low dose of 3 mg Mectizan will not prevent encephalopathy following treatment for onchocerciasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11258063

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  8 in total

1.  Operationalization of the test and not treat strategy to accelerate the elimination of onchocerciasis and lymphatic filariasis in Central Africa.

Authors:  Joseph Kamgno; Hugues C Nana-Djeunga; Sébastien D Pion; Cédric B Chesnais; Amy D Klion; Charles D Mackenzie; Thomas B Nutman; Michel Boussinesq
Journal:  Int Health       Date:  2018-03-01       Impact factor: 2.473

2.  A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia.

Authors:  Joseph Kamgno; Patrick Nguipdop Djomo; Sébastien D Pion; Björn Thylefors; Michel Boussinesq
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

3.  Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of Loa loa Microfilariaemia with Prolonged Repeated Courses of Albendazole.

Authors:  Divine B Arrey-Agbor; Hugues C Nana-Djeunga; Aude E Mogoung-Wafo; Mirabelle Mafo; Christian Danwe; Joseph Kamgno
Journal:  Am J Trop Med Hyg       Date:  2018-05-03       Impact factor: 2.345

4.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

5.  Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment.

Authors:  Samuel Wanji; Ebanga-Echi J Eyong; Nicholas Tendongfor; Che J Ngwa; Elive N Esuka; Arnaud J Kengne-Ouafo; Fabrice R Datchoua-Poutcheu; Peter Enyong; Dalen Agnew; Rob R Eversole; Adrian Hopkins; Charles D Mackenzie
Journal:  PLoS Negl Trop Dis       Date:  2017-07-07

6.  Effect of a Single Standard Dose (150-200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis.

Authors:  Sébastien D Pion; Jules Brice Tchatchueng-Mbougua; Cédric B Chesnais; Joseph Kamgno; Jacques Gardon; Jean-Philippe Chippaux; Stéphane Ranque; Jean-Christophe Ernould; André Garcia; Michel Boussinesq
Journal:  Open Forum Infect Dis       Date:  2019-01-11       Impact factor: 3.835

7.  Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators of Loa loa Infection.

Authors:  Hugues C Nana-Djeunga; Cédric G Lenou-Nanga; Cyrille Donfo-Azafack; Linda Djune-Yemeli; Floribert Fossuo-Thotchum; André Domche; Arsel V Litchou-Tchuinang; Jean Bopda; Stève Mbickmen-Tchana; Thérèse Nkoa; Véronique Penlap; Francine Ntoumi; Joseph Kamgno
Journal:  Pathogens       Date:  2020-12-12

8.  Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial.

Authors:  Jérémy T Campillo; Paul Bikita; Marlhand Hemilembolo; Frédéric Louya; François Missamou; Sébastien D S Pion; Michel Boussinesq; CédricB Chesnais
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.